For research use only. Not for therapeutic Use.
TG693 (CAT: I037176) is an inhibitor that selectively targets CLK1 (cdc2-like kinase 1). CLK1 is a protein kinase involved in the regulation of pre-mRNA splicing, which is a critical step in gene expression. By inhibiting CLK1, TG693 can modulate alternative splicing events and potentially influence the expression of specific protein isoforms. This selective ATP-competitive inhibitor shows promise as a tool compound for studying CLK1 function and as a potential therapeutic agent for diseases where dysregulated splicing is implicated, such as cancer and neurodegenerative disorders.
| Catalog Number | I037176 |
| CAS Number | 885272-55-9 |
| Synonyms | TG-693; TG693; TG 693 |
| Molecular Formula | C12H9N3 |
| Purity | 98% |
| Target | CDK |
| Solubility | Soluble in DMSO |
| Appearance | Solid powder |
| Storage | Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years). |
| IUPAC Name | 5-Pyridin-4-yl-1H-indazole |
| InChI | InChI=1S/C12H9N3/c1-2-12-11(8-14-15-12)7-10(1)9-3-5-13-6-4-9/h1-8H,(H,14,15) |
| InChIKey | CILGVAIRQUNMLT-UHFFFAOYSA-N |
| SMILES | C12=C(NN=C2)C=CC(C3=CC=NC=C3)=C1 |
| Reference | 1: Sako Y, Ninomiya K, Okuno Y, Toyomoto M, Nishida A, Koike Y, Ohe K, Kii I, Yoshida S, Hashimoto N, Hosoya T, Matsuo M, Hagiwara M. Development of an orally available inhibitor of CLK1 for skipping a mutated dystrophin exon in Duchenne muscular dystrophy. Sci Rep. 2017 May 30;7:46126. doi: 10.1038/srep46126. PubMed PMID: 28555643; PubMed Central PMCID: PMC5448077. |
